FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Ehrlich Christopher B
2. Issuer Name and Ticker or Trading Symbol

eFFECTOR Therapeutics, Inc. [ EFTR ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

C/O EFFECTOR THERAPEUTICS, INC., 11120 ROSELLE ST SUITE A
3. Date of Earliest Transaction (MM/DD/YYYY)

8/25/2021
(Street)

SAN DIEGO, CA 92121
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 8/25/2021  C  142168 A$0.00 142168 I By Locust Walk Partners LLC (1)
Common Stock 8/25/2021  C  1034 A$0.00 1034 I By Locust Walk Partners LLC (2)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Class B Common Stock  (3)(4)8/25/2021  D     132832   (3)(4) (3)(4)Common Stock 132832 $0.00 142168 (5)I By Locust Walk Partners LLC (1)
Class B Common Stock  (3)8/25/2021  C     142168   (3) (3)Common Stock 142168  (3)0 I By Locust Walk Partners LLC (1)
Class B Common Stock  (3)8/25/2021  D     966   (3)(4) (3)(4)Common Stock 966 $0.00 1034 (5)I By Locust Walk Partners LLC( (2)
Class B Common Stock  (3)8/25/2021  C     1034   (3) (3)Common Stock 1034  (3)0 I By Locust Walk Partners LLC (2)

Explanation of Responses:
(1) Represents shares held directly by the Sponsor, of which Locust Walk Partners LLC ("LWP") is a member. LWP has allocated these shares to the reporting person.
(2) Represents shares held directly by the Sponsor, of which LWP is a member. LWP has allocated these shares to the reporting person's spouse.
(3) On August 25, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of May 26, 2021 (the "Merger Agreement"), by and among the Issuer (f/k/a Locust Walk Acquisition Corp.), Locust Walk Merger Sub, Inc. ("Merger Sub"), and eFFECTOR Therapeutics, Inc. ("Old eFFECTOR"), Merger Sub merged with and into Old eFFECTOR with Old eFFECTOR surviving as a wholly owned subsidiary of the Issuer (the "Merger"). In connection with and upon consummation of the Merger, each of the Issuer's outstanding shares of Class B Common Stock automatically converted into one share of Class A Common Stock and such shares of Class A Common Stock were automatically reclassified in shares of common stock.
(4) Pursuant to an agreement by and between the Issuer and Locust Walk Sponsor, LLC (the "Sponsor"), concurrent with the consummation of the Merger, these shares of Class B Common Stock were forfeited to the Issuer immediately prior to the Merger.
(5) As a former principal of the manager of the Sponsor, the reporting person previously reported all securities held by the Sponsor. As of the date hereof, the reporting person is no longer a principal of the entity with control over the securities held by the Sponsor, accordingly, this report only includes securities to the extent of the reporting person's and his spouse's pecuniary interest therein.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Ehrlich Christopher B
C/O EFFECTOR THERAPEUTICS, INC.
11120 ROSELLE ST SUITE A
SAN DIEGO, CA 92121
X



Signatures
/s/ Michael Byrnes, Attorney-in-Fact for Chris Ehrlich8/25/2021
**Signature of Reporting PersonDate

eFFECTOR Therapeutics (NASDAQ:EFTR)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more eFFECTOR Therapeutics Charts.
eFFECTOR Therapeutics (NASDAQ:EFTR)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more eFFECTOR Therapeutics Charts.